Compare Incyte Corporation (INCY) vs TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock (TTWO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock — how do they compare? Incyte Corporation trades at $115.71 (market cap $23.11B), while TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock trades at $238.71 (market cap $44.37B). The key difference: TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock is the larger of the two by market cap, and Incyte Corporation is trading nearer its 52-week high, TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock nearer its low. Which is the better fit depends on your goals.
| INCY | TTWO | |
|---|---|---|
Market Cap | $23.11B | $44.37B |
Sector | Health | Media |
52-Week High | $118.52 | $262.29 |
52-Week Low | $67.38 | $189.69 |
Enterprise Value | $19.13B | $45.34B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INCY trades at $115.66, down 1.36% on the day, with a bullish technical signal from moving averages and strong fundamental performance including a 25.02% net income margin for 2025. Recent positive news includes regulatory approvals for Opzelura in Europe and the acquisition of Vega Therapeutics, expanding its hematology portfolio. Revenue grew to $5.14 billion in 2025, with earnings beating expectations in two of the last three quarters.
The outlook remains positive given robust profitability, pipeline advancements, and a majority analyst buy rating, though risks include competitive pressures and reliance on key drug performance. The stock's current price is slightly above the consensus target of $112.78, suggesting near-term consolidation potential amid longer-term growth catalysts.
Take-Two Interactive (TTWO) trades at $239.04, up 1.0% on the day, with a bullish technical outlook as the price approaches resistance near $240. The company reported three consecutive quarterly EPS beats but posted a net loss of -$4.48B in FY2025, with revenue growth to $5.63B. Investor focus remains on the upcoming Grand Theft Auto VI release, driving positive sentiment despite recent profitability challenges.
The stock offers significant upside to the consensus price target of $302.50, supported by strong analyst buy ratings (78.95%), but carries risks from high debt levels and negative margins. Near-term catalysts include Q2 2026 earnings on August 7, 2026, though execution on GTA VI and cost management are critical for sustained recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock
Found in 1993, Take-Two consists of three wholly owned labels, Rockstar Games, 2K, and Zynga. The firm is one of the world's largest independent video game publishers on consoles, PCs, smartphones, and tablets. Take-Two's franchise portfolio is headlined by Grand Theft Auto (345 million units sold) and contains other well-known titles such as NBA 2K, Civilization, Borderlands, Bioshock, and Xcom. Zynga mobile titles include Farmville, Empires & Puzzles, and CSR Racing.
Read more on TTWO →
